New methods in laboratory diagnostics of dilated cardiomyopathy

Cardiology Journal

Volumn 15, Issue 4, 2008, Pages 388-395

  Bielecka Dabrowa, Agata ^a   Wierzbicka, Magdalena ^a   Dabrowa, Marek ^a   Goch, Aleksander ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiac troponins; Dilated cardiomyopathy; Inflammatory cytokines; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CA 125 ANTIGEN; COLLAGENASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; OSTEOPONTIN; TROPONIN C; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; BIOLOGICAL MARKER; CYTOKINE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY THROMBOSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; ECHOCARDIOGRAPHY; GENETIC ASSOCIATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HUMAN; LABORATORY TEST; NONHUMAN; PATHOGENESIS; RISK ASSESSMENT; TREATMENT PLANNING; BLOOD; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HOSPITALIZATION; MALE; METABOLISM; METHODOLOGY; MONITORING; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CYTOKINES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; MONITORING, PHYSIOLOGIC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TROPONIN T;

EID: 55249113941     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. DeSanctis RW, Dec GW. The cardiomyopathies. In: Dale D, Federman D eds. Scientific American Medicine. Scientific American, New York 2000; 1: 28.
2. Wynne J, Braunwald E. The cardiomyopathies and myocarditis. In: Braunwal E, Zipes DP, Libby P eds. Heart disease. WB Saunders Company, Philadelphia 2001: 1751-1806.
3. Charron P, Komajda M. Genes and their polymorphisms in mono-and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure. Pharmacogenomics, 2002; 3: 367-378.
4. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of European Society of Cardiology Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005). Eur Heart J, 2005; 26: 1115-1140.
5. Zaida M, Robert A, Fesler R et al. Dispersion of ventricular repolarization in dilated cardiomyopathy. Eur Heart J, 1997; 18: 1129-1134.
6. Xiao HB, Roy C, Fujimoto S et al. Natural history of anormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol, 1996; 53: 163-170.
7. Binanay C, Califf RM, Hasselblad V et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. JAMA, 2005; 295: 1625-1633.
8. Feigenbaum H, Armstrong WF, Ryan T. Faigenbaum's echocardiography. 6th Ed. Lippincot Williams and Wilkins, Philadelphia 2006: 537-546.
9. Edwards BS, Zimmerman RS, Schab TR et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res, 1988; 62: 191-195.
10. Wiese S, Breyer T, Dragu A et al. Gene expression of brain natriuretic peptide In isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length. Circulation, 2000; 102: 3074-3079.
11. Bettencourt PM. Clinical usefulness of B-type natriuretic peptide measurement: Present and future perspectives. Heart, 2005; 91: 1489-1494.
12. Bilińska ZT, Michalak E, Grzybowski J et al. Kardiomiopatia rozstrzeniowa - badanie prospektywne rodzin. Kardiol Pol, 2002; 56: 36-39.
13. Nakamura M, Endo H, Nasu M et al. Value of plasma B type natriuretic peptide measurement for heart disease screening in Japanese population. Heart, 2002; 87: 131-135.
14. Januzzi JL, Chen-Tournoux AA, Moe G. Amono-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol, 2008; 3: S29-S38.
15. Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS. Troponin, B-type natriuretic peptides and outcomes in severe heart failure: Differences between ischemic and dilated cardiomyopathies. Clin Cardiol, 2007; 30: 245-250.
16. Ishikawa C, Tsutamoto T, Fujii M, Sakai H, Tanaka T, Horie M. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J, 2006; 70: 857-863.
17. Maeda K, Tsutamoto T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end - diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J, 1998; 135: 825-832.
18. Kazanegra R, Cheng V, Garcia A et al. A Rapie-test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Cardiac Fail, 2001; 7: 21-29.
19. Parsonage WA, Galbraith AJ, Koerbin GL et al. Value of B-type natriuretic peptide for identyfying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol, 2005; 95: 883-885.
20. O'Neil JO, Bott-Silverman CE, McRae AT 3rd et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J, 2005; 149: 363-369.
21. Moe GW. B-type natriuretic peptide in heart failure. Curr Opin Cardiol, 2006; 21: 208-214.
22. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol, 2001; 37: 1228-1233.
23. Redfield MM, Rodeheffer RJ, Jacobson SJ et al. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol, 2002; 40: 976-982.
24. McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis, 2003; 41: 571-579.
25. McCord J, Mundy BJ, Hudson MP et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med, 2004; 164: 2247-2252.
26. Mehra MR, Ubek PA, Park MH et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol, 2004; 42: 1590-1595.
27. Bibbns-Domingo K, Ansami M, Schiller NB et al. B-type natriuretic peptide and ischemia In patients with stable coronary disease? Data from the Heart and Soul Study. Circulation, 2003; 108: 2987-2992.
28. Torbicki A, Pruszczyk P, Kurzyna M. Pulmonary emboliom: Role of echocardiography and of biological markers. Ital Heart J, 2005; 6: 805-810.
29. Fijałkowska A, Kurzyna M, Torbicki A et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest, 2006; 129: 1313-1321.
30. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail, 2004; 6: 355-358.
31. Chang AN, Parvatiyar MS, Potter JD. Troponin and cardiomyopathy. Biochem Biophys Res Commun, 2008; 369: 74-81.
32. Nellessen U, Goder S, Schobre R, Abawi M, Hecker H, Tschöke S. Serial analysis of troponin I levels in patients with ischemic and nonischemic dilated cardiomyopathy. Clin Cardiol, 2006; 29: 219-224.
33. Miller WL, Hartman KA, Burritt MF et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: The importance of change over time. Circulation, 2007; 116: 249-257.
34. Sato Y, Yamada T, Taniguchi R et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation, 2001; 103: 369.
35. Kelllwellis-Opara A, Dörner A, Poller WC et al. Autoimmunological features in inflammatory cardiomyopathy. Clin Res Cardiol, 2007; 5: 22.
36. Mandi Y, Högye M, Talha EM, Skolak E, Csanady M. Cytokine production and antibodies against heart srock protein 60 in cardiomyopathies of differ origins. Pathobiology, 2000; 68: 150-158.
37. Remme WJ. Pharmacological modulation of cardiovascular remodeling: A guide to heart failure therapy. Cardiovasc Drugs Ther, 2003; 17: 349-360.
38. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanism in heart failure: The cytokin hypothesis. J Card Fail, 1996; 2: 243-249.
39. Tentolouris C, Tousoulis D, Antoniades C et al. Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. Int J Cardiol, 2004; 94: 301-305.
40. Limas CJ, Hasikidis C, Iakovou J et al. Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur J Clin Invest, 2003; 33: 443-448.
41. Brooksbank R, Woodiwiss A, Sliwa K et al. Sustained white cell cytokine activation in idiopathic dilated cardiomyopathy despite haemodynamic improvement with medical therapy. Cardiovasc J S Afr, 2005; 16: 200-204.
42. Gürgün C, Ildizli M, Yavuzgil O et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol, 2007; 21: 102-107.
43. Domański M, Coady S, Fleg J, Tian X, Sachdev V. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy; from the Beta Blocker evaluation of survival trial (BEST). Am J Cardiol, 2007; 99: 1448-1450.
44. Sampietro T, Negliz D, Bionda A et al. Inflammatory markers and serum lipids in idiopathic dilated cardiomyopathy. Am J Cardiol, 2005; 96: 1718-1720.
45. Soejima H, Irie A, Fukunaga T et al. Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ J. 2007; 71: 1879-1884.
46. Satoh M, Nakamura M, Akatsu T et al. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail, 2005; 7: 755-762.
47. Kouris NT, Kontogianni DD, Papoulia EP et al. Clinical and prognostic value of elevated CA125 levels in patients with congestive heart failure. Hellenic J Cardiol, 2006; 47: 269-274.
48. Núńez J, Núńez E, Consuegra L et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart, 2007; 93: 716-721.
49. Filipiak KJ, Folga A, Grabowski MS et al. Concomitant estimation of NT-pro-BNP and CA125 for better outcome prognosis in congestive heart failure. Eur J Heart Fail Suppl, 2007; 6: 22.
50. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure. Circulation, 2003; 107: 1991-1997.